Oral Oncology
Volume 38, Issue 7 , Pages 686-690 , October 2002

A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma

  • J.S McCarthy

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    • ,
  • I.F Tannock

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    • ,
  • P Degendorfer

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    • ,
  • T Panzarella

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    • ,
  • M Furlan

      Affiliations

    • Aventis Pharma, 2150 St. Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8
    • ,
  • L.L Siu

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    • Corresponding Author InformationCorresponding author

Received 28 September 2001 ,Accepted 9 December 2001.

References 

  1. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, et al.  Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J. Clin. Oncol. 2000;18:1320–1324
  2. Siu LL, Czaykowski P, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J. Clin. Oncol. 1998;16:2514–2521
  3. Azli N, Fandi A, Bachouchi M, Rahel M, Lianes P, Wibault P, et al.  Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J. Sci. Am. 1995;1:222–229
  4. Yeo W, Leung TW, Leung SF, Teo PM, Chan AT, Lee WY, et al.  Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother. Pharmacol. 1996;38:466–470
  5. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, et al.  Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer. 1995;76:2186–2192
  6. Fountzilas G, Skarlos D, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, et al.  Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. Ann. Oncol. 1997;8:451–455
  7. Specht L, Larsen S, Hansen H. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann. Oncol. 2000;11:845–849
  8. Pivot X, Cals L, Cupissol D, Guardiola E, Tchiknavorian X, Guerrier P, et al.  Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology. 2001;60:66–71
  9. Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann. Oncol. 1998;9:327–329
  10. Tan E, Khoo K, Wee J, Fong KW, Lee KS, Lee KM, et al.  Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann. Oncol. 1999;10:235–237

PII: S1368-8375(01)00134-8

Oral Oncology
Volume 38, Issue 7 , Pages 686-690 , October 2002

Article Tools

* Image Usage & Resolution